Processa Pharmaceuticals, Inc.
General ticker "PCSA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.5M (TTM average)
Processa Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -20.8%.
Estimated limits based on current volatility of 2.8%: low 2.06$, high 2.18$
Factors to consider:
- Total employees count: 13 (-13.3%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Need for additional capital, Inability to achieve profitability, Regulatory and compliance, Clinical trial failure, Intellectual property risks
- Current price 15.8% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.49$, 8.18$]
- 2026-12-31 to 2027-12-31 estimated range: [1.52$, 5.34$]
Financial Metrics affecting the PCSA estimates:
- Positive: with PPE of -0.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -257.82 <= 0.28
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 71.38 > 63.63
Short-term PCSA quotes
Long-term PCSA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $11.46MM | $12.05MM | $13.99MM |
| Operating Income | $-11.46MM | $-12.05MM | $-13.99MM |
| Non-Operating Income | $0.34MM | $0.20MM | $0.42MM |
| R&D Expense | $5.80MM | $7.27MM | $7.81MM |
| Income(Loss) | $-11.12MM | $-11.85MM | $-13.56MM |
| Net Income(Loss)* | $-11.12MM | $-11.85MM | $-13.56MM |
| Stockholders Equity | $4.99MM | $1.70MM | $5.58MM |
| Assets | $5.79MM | $3.23MM | $7.81MM |
| Operating Cash Flow | $-8.06MM | $-11.25MM | $-11.39MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $-0.00MM | $-0.85MM |
| Financing Cash Flow | $6.27MM | $7.73MM | $16.58MM |
| Earnings Per Share** | $-211.99 | $-96.82 | $-10.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.